Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-24 7:57 pm Sale |
2025-03-20 | 13D | ARS Pharmaceuticals, Inc. SPRY |
Flynn James E | 10,514,657 10.720% |
-563,270 (-5.08%) |
Filing History |
| 2025-03-03 7:04 pm Purchase |
2025-02-27 | 13D | BiomX Inc. PHGE |
Flynn James E | 15,558,445 9.990% |
0 (+0.00%) |
Filing History |
| 2025-02-25 9:18 pm Sale |
2025-02-21 | 13D | Singular Genomics Systems, Inc. OMIC |
Flynn James E | 1,000 100.000% |
-248,495 (-99.60%) |
Filing History |
| 2025-02-13 09:40 am Sale |
2025-02-13 | 13G | DocGo Inc. DCGO |
Flynn James E | 5,051,500 4.950% |
-4,014,638 (-44.28%) |
Filing History |
| 2025-02-13 09:39 am Purchase |
2024-12-31 | 13G | Indivior PLC INDV |
Flynn James E | 8,883,160 7.160% |
1,519,950 (+20.64%) |
Filing History |
| 2025-02-13 08:59 am Sale |
2024-12-31 | 13G | Ventyx Biosciences, Inc. VTYX |
Flynn James E | 534,737 0.760% |
-6,180,764 (-92.04%) |
Filing History |
| 2025-02-13 08:58 am Sale |
2024-12-31 | 13G | Prelude Therapeutics Incorporated PRLD |
Flynn James E | 0 0.000% |
-4,133,000 (Position Closed) |
Filing History |
| 2025-02-13 08:57 am Sale |
2024-12-31 | 13G | Kura Oncology, Inc. KURA |
Flynn James E | 0 0.000% |
-5,312,733 (Position Closed) |
Filing History |
| 2025-02-13 08:57 am Sale |
2024-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
Flynn James E | 3,133,011 2.630% |
-3,096,623 (-49.71%) |
Filing History |
| 2025-02-13 08:56 am Sale |
2024-12-31 | 13G | Alignment Healthcare, Inc. ALHC |
Flynn James E | 7,304,302 3.810% |
-3,561,211 (-32.78%) |
Filing History |
| 2025-02-13 08:55 am Sale |
2024-12-31 | 13G | Nuvalent, Inc. NUVL |
Flynn James E | 23,582,278 27.590% |
-1,997,612 (-7.81%) |
Filing History |
| 2025-01-28 5:40 pm Sale |
2025-01-27 | 13D | Acutus Medical, Inc. AFIB |
Flynn James E | 5,492,725 9.100% |
-4,213,132 (-43.41%) |
Filing History |
| 2025-01-23 9:16 pm Unchanged |
2025-01-21 | 13D | Acutus Medical, Inc. AFIB |
Flynn James E | 9,705,857 9.100% |
0 (Unchanged) |
Filing History |
| 2024-12-26 8:55 pm Unchanged |
2024-12-22 | 13D | Singular Genomics Systems, Inc. OMIC |
Flynn James E | 249,495 6.620% |
0 (Unchanged) |
Filing History |
| 2024-12-16 9:52 pm Purchase |
2024-12-12 | 13D | Acutus Medical, Inc. AFIB |
Flynn James E | 9,705,857 9.100% |
28,000 (+0.29%) |
Filing History |
| 2024-11-15 6:03 pm Purchase |
2024-11-08 | 13G | Indivior PLC INDV |
Flynn James E | 7,363,210 5.800% |
7,363,210 (New Position) |
Filing History |
| 2024-11-14 09:56 am Purchase |
2024-09-30 | 13G | DocGo Inc. DCGO |
Flynn James E | 9,066,138 8.880% |
3,745,999 (+70.41%) |
Filing History |
| 2024-11-14 09:55 am Sale |
2024-09-30 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
Flynn James E | 6,229,634 5.220% |
-2,659,267 (-29.92%) |
Filing History |
| 2024-11-14 09:03 am Sale |
2024-09-30 | 13G | AdaptHealth Corp. AHCO |
Flynn James E | 23,758,393 7.220% |
-3,896,530 (-14.09%) |
Filing History |
| 2024-11-14 09:02 am Sale |
2024-09-30 | 13G | Verastem, Inc. VSTM |
Flynn James E | 0 0.000% |
-1,538,461 (Position Closed) |
Filing History |